Skip to main content
. 2018 Jun 5;9(13):2232–2236. doi: 10.7150/jca.24557

Table 2.

The adverse events with maximum severity (Grade 3/4) across all cycles of treatment

Frequency (%)
all patients (N=36)
Frequency (%)
first line patients (N=30)
Toxicity (Grade 3/4)
Hematologic
Neutropenia 21 (58.3) 17 (56.7)
Leukopenia 20 (55.6) 17 (56.7)
Thrombocytopenia 9 (25.0) 8 (26.7)
Anemia 10 (27.8) 9 (30.0)
Non-hematological
Hepatotoxicity None None
Nephrotoxicity None None
Nausea/vomiting None None